Hayward, Calif., Jan. 24 /PRNewswire/ -- Metabolex, Inc. today announced findings showing the molecular and cellular differences between metaglidasen, a novel oral Insulin sensitizer in clinical development for the treatment of type 2 Diabetes, and rosiglitazone and pioglitazone, currently marketed Insulin sensitizers of the TZD (thiazolidinedione) class. These preclinical findings demonstrated that metaglidasen provided glycemic control and lipid-lowering activity equivalent to the TZDs with a significantly improved side effect profile, including less weight gain and Edema (fluid retention). The data will be presented today in Vancouver at Keystone Symposia's Scientific Conference on Diabetes Mellitus and the Control of Cellular Energy Metabolism during the Poster Session (poster #342).
|
| ||
| No Ebay Marketplace Listings Found | ||
More results for
Edema on Google
Google is currently the number one search engine on the net. If you want to find anything on
the web related to Edema then Google is a great place to start.
More results for Edema on Overture
Overture is the largest partner search engine on the web. If you are
interesting in buying a product related to Edema or obtaining services related to Edema then
Overture is the place to start.
Try Asking about
Edema
Ask.com may produce some results for Edema that you can not find anywhere else. Ask
will also show you more searches related to Edema and provide an automatic picture search for
Edema